Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc. (Nasdaq: ALGS) is a clinical-stage biotechnology company developing therapies for liver diseases and viral infections. Its pipeline includes pevifoscorvir sodium, an oral candidate for chronic hepatitis B virus (HBV) infection; ALG-055009, a thyroid hormone receptor beta agonist being… From the company’s description.
Over the twelve months to Sep 30, 2026, Aligos Therapeutics, Inc. reported revenue of $27.99M, up 966.9% from a year earlier, and a net loss of $66.28M. Its operating margin was −259.1%, and operations used $68.37M in cash. In fiscal 2025, it reported revenue of $2.19M, down 39.5% from fiscal 2024, and a net loss of $24.19M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Aligos Therapeutics, Inc. does
In the company’s own words
Aligos Therapeutics, Inc. (Nasdaq: ALGS) is a clinical-stage biotechnology company developing therapies for liver diseases and viral infections. Its pipeline includes pevifoscorvir sodium, an oral candidate for chronic hepatitis B virus (HBV) infection; ALG-055009, a thyroid hormone receptor beta agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH) and obesity; and ALG-097558, a coronavirus protease inhibitor. The company also pursues preclinical programs, including antisense oligonucleotide candidates for HBV and hepatitis delta infection. Its research uses small-molecule and oligonucleotide platforms, and it works with contract manufacturers to supply candidates for nonclinical and clinical studies. The company has no approved products for commercial sale and has not established sales, marketing, or distribution capabilities. It licenses and collaborates with external organizations on selected technologies and development programs, while retaining worldwide development and commercialization rights to its clinical candidates, including through exclusive licenses. The candidates are intended for patients with chronic viral infections, MASH, or obesity.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1799448
- SIC
- 2836
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Aligos Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Aligos Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Aligos Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Aligos Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Aligos Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”